Hepatitis C Therapy - MIGENIX Third Quarter Fiscal 2006 Financial Results Conference Call & Web Cast Notification

MIGENIX Third Quarter Fiscal 2006 Financial Results Conference Call & Web Cast Notification
[Press Release] PR Newswire via Yahoo! Finance - Mar 02 12:58 PM
MIGENIX Inc. , a clinical-stage developer of drugs for infectious and degenerative diseases, will host a conference call and web cast on Wednesday, March 8th, 2006 at 11:00 a.m. ET to discuss financial results for the third quarter of fiscal year 2006 ended January 31, 2006 and provide an update on company activities.Save to My Web

Human Genome Sciences Reports Positive Interim Results of Phase 2 Trial of Albuferon(TM) In Combination With Ribavirin
[Press Release] PR Newswire via Yahoo! Finance - Mar 14 5:01 AM
Human Genome Sciences, Inc. today reported the interim results of a Phase 2 clinical trial to evaluate the safety, tolerability and efficacy of Albuferon in combination with ribavirin in patients with chronic hepatitis C who failed to respond to previous interferon alpha-based treatment regimens.Save to My Web

euro adhoc: Intercell AG / Financial Figures/Balance Sheet / Intercell announces preliminary 2005 full year
vwd.de - Mar 05 10:43 PM
Disclosure announcement transmitted by euro adhoc. The issuer is responsible for the content of this announcement.Save to My Web

euro adhoc: Intercell AG / Financial Figures/Balance Sheet / Intercell announces preliminary 2005 full year results:
Presseportal - Mar 05 10:29 PM
06.03.2006 Intercell announces preliminary 2005 full year results: Good progress in product development - significant increase in revenues - strong cash ...Save to My Web

ViRexx Presents Hepatitis C Chimigen'TM' Technology at Baculovirus & Insect Cell Culture Annual Meeting
[Press Release] Business Wire via Yahoo! Finance - Feb 22 5:00 AM
EDMONTON, Alberta----Feb. 22, 2006--ViRexx Medical Corp. , a company focused on immunotherapy treatments for certain cancers, chronic hepatitis B & C and embolotherapy treatments for tumors, today announced that Rajan George, Ph.D., Vice President Research and Development of ViRexx, made a presentation about the Company's Chimigen technology for hepatitis C at the 9th Annual Meeting of the Save to My Web